Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second View: Looking at the Alzheimer's Landscape with a focus on Lilly's Donanemab compared to Biogen's Leqembi.

Ticker(s): LLY, BIIB

Who's the expert?

Institution: Neurology Center of Lumberton

board-certified in Neurology and Sleep Medicine
expertise in diagnosing & treating Alzheimer's disease, Vascular dementia, Diffuse Lewy body dementia, Guillain-Barre syndrome and CIDP(chronic inflammatory demyelinating polyneuropathy),
manages treatment for 36 patients with CIDP and 120 patients with Alzheimer's Disease

Interview Goal

to discuss the standard of care and the potential of Donanemab being developed by Eli Lilly, and the use of lecanemab including the phase 3 TRAILBLAZER-ALZ 2 clinical trial data on Donanemab (LY3002813).

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.